Atomic Alchemy

Atomic Alchemy was dedicated to revolutionizing the production of nuclear materials essential for nuclear medicine. Their core mission involved establishing a reactor network to reliably generate radiopharmaceuticals, which are critical components in biological tracers, diagnostic imaging, and cancer treatments.

The global supply of Molybdenum-99, a key isotope utilized in the majority of nuclear medicine procedures, was primarily sourced from a limited number of aging, government-operated research reactors located overseas. The age of these reactors presented a significant risk to the stability of the supply chain, a critical vulnerability given the nature of radioactive materials.

Atomic Alchemy aimed to address not only the Molybdenum-99 shortage but also the broader challenges in sourcing other reactor-based isotopes. Many promising cancer therapies were hindered by the difficulty in obtaining sufficient materials for clinical trials, and research into new isotopes was often stifled by supply chain complexities. To overcome these obstacles, Atomic Alchemy embarked on a mission to develop the world's first scalable radioisotope production facility, featuring privately-owned nuclear reactors specifically designed for radioisotope production.